Bluebird Bio Expands On Partnership To Take A Lead In Immuno-Oncology – Seeking Alpha
Seeking Alpha |
Bluebird Bio Expands On Partnership To Take A Lead In Immuno-Oncology
Seeking Alpha Bluebird Bio expands license agreement for two additional TCR targets. There is a need for TCRs, because CAR–T are strong but can’t target tumor proteins that are inside of cells only those that are expressed on the cell’s surface. Bluebird Bio will … bluebird bio expands US$1bn deal with MediGeneEuropean Biotechnology |
|
Whanganui MS sufferer Briar Novis fundraising for stem cell treatment in Russia
New Zealand Herald Briar Novis is now past the halfway mark in her attempt to get the treatment she says she needs to halt progress of her multiple sclerosis. The Whanganui woman planned to travel to Russia for radical stem cell treatment she couldn’t get here – but she … |
PMLiVE |
Breakthrough Device status for novel blood filtering immunotherapy
PMLiVE This year has seen the FDA grant a flurry of Breakthrough Device Designations, and the latest is from Immunicom and its proprietary novel blood filtering technology called ‘Immunopheresis’. The San Diego-based firm’s lead therapy focuses on removing … |
PMLiVE |
Breakthrough Device status for novel blood filtering immunotherapy
PMLiVE This year has seen the FDA grant a flurry of Breakthrough Device Designations, and the latest is from Immunicom and its proprietary novel blood filtering technology called ‘Immunopheresis’. The San Diego-based firm’s lead therapy focuses on removing … |
Endpoints News |
Waksal’s gene therapy spinoff MeiraGTx says it’s time to fly with an $86M IPO
Endpoints News Three years after Sam Waksal’s Kadmon spun out its gene therapy tech into a startup called MeiraGTx, the New York-based biotech says it’s ready to come out to play on Nasdaq. Waksal, an ex-con once sentenced to prison for his insider trading conviction … |